SG11201908825TA - Stable multispecific antibodies - Google Patents

Stable multispecific antibodies

Info

Publication number
SG11201908825TA
SG11201908825TA SG11201908825TA SG11201908825TA SG 11201908825T A SG11201908825T A SG 11201908825TA SG 11201908825T A SG11201908825T A SG 11201908825TA SG 11201908825T A SG11201908825T A SG 11201908825TA
Authority
SG
Singapore
Prior art keywords
international
paris
pct
fremiet
avenue
Prior art date
Application number
Other languages
English (en)
Inventor
Eugene Zhukovsky
Olivier Leger
Richard J Morse
Original Assignee
Biomunex Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomunex Pharmaceuticals filed Critical Biomunex Pharmaceuticals
Publication of SG11201908825TA publication Critical patent/SG11201908825TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201908825T 2017-03-27 2018-03-27 Stable multispecific antibodies SG11201908825TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305353 2017-03-27
PCT/EP2018/057819 WO2018178101A1 (fr) 2017-03-27 2018-03-27 Anticorps multispécifiques stables

Publications (1)

Publication Number Publication Date
SG11201908825TA true SG11201908825TA (en) 2019-10-30

Family

ID=58701560

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908825T SG11201908825TA (en) 2017-03-27 2018-03-27 Stable multispecific antibodies

Country Status (13)

Country Link
US (1) US11560437B2 (fr)
EP (1) EP3601366A1 (fr)
JP (2) JP7432365B2 (fr)
KR (1) KR20190141154A (fr)
CN (1) CN111094355A (fr)
AU (1) AU2018241881A1 (fr)
BR (1) BR112019019998A2 (fr)
CA (1) CA3057567C (fr)
IL (1) IL269559B2 (fr)
MX (1) MX2019011585A (fr)
SG (1) SG11201908825TA (fr)
WO (1) WO2018178101A1 (fr)
ZA (1) ZA201906981B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017162890A1 (fr) 2016-03-25 2017-09-28 Biomunex Pharmaceuticals Molécules de liaison à cd38 et à pd-l1
WO2017186950A1 (fr) * 2016-04-28 2017-11-02 Biomunex Pharmaceuticals Anticorps bispécifiques ciblant l'egfr et her2
JP2020503873A (ja) 2017-01-09 2020-02-06 ビオミューネクス・ファルマシューティカルＢｉｏｍｕｎｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ 多重特異的抗体を調製するためのポリペプチドリンカー
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
US20240010754A1 (en) * 2020-12-03 2024-01-11 Jiangsu Hengrui Medicine Co., Ltd. Multispecific antigen binding protein
CN114106192B (zh) * 2021-12-20 2024-06-14 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
BR112013023918A2 (pt) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
EP2543680A1 (fr) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Fragment Fab d'anticorps multi-spécifiques mutés
US9738707B2 (en) * 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US11851476B2 (en) * 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
WO2014028776A1 (fr) 2012-08-15 2014-02-20 Zyngenia, Inc. Complexes multispécifiques monovalents et multivalents et leurs utilisations
EP2954056A4 (fr) * 2013-02-08 2016-09-21 Stemcentrx Inc Nouvelles constructions multispécifiques
SG11201603244VA (en) 2013-11-04 2016-05-30 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
KR20160085324A (ko) * 2013-11-13 2016-07-15 자임워크스 인코포레이티드 Her2를 표적화하는 1가 항원 결합 작제물을 사용하는 방법
ME03666B (fr) 2014-03-28 2020-10-20 Xencor Inc Anticorps bispécifiques se liant à cd38 et cd3
US10392438B2 (en) 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
EP3172235A2 (fr) 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispécifiques, anticorps anti-cd3 activables multispécifiques et procédés d'utilisation de ces anticorps
GB201414823D0 (en) * 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
KR20240093813A (ko) 2015-04-24 2024-06-24 제넨테크, 인크. 다중특이적 항원-결합 단백질
WO2017162890A1 (fr) 2016-03-25 2017-09-28 Biomunex Pharmaceuticals Molécules de liaison à cd38 et à pd-l1
WO2017186950A1 (fr) 2016-04-28 2017-11-02 Biomunex Pharmaceuticals Anticorps bispécifiques ciblant l'egfr et her2
WO2018027204A1 (fr) 2016-08-05 2018-02-08 Genentech, Inc. Anticorps multivalents et multiépitopiques ayant une activité agoniste et procédés d'utilisation
JP2020503873A (ja) 2017-01-09 2020-02-06 ビオミューネクス・ファルマシューティカルＢｉｏｍｕｎｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ 多重特異的抗体を調製するためのポリペプチドリンカー
MX2020003145A (es) 2017-09-22 2020-07-29 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos.
GB201814562D0 (en) 2018-09-07 2018-10-24 Hummingbird Bioscience Pte Ltd Vista antigen-binding molecules
WO2019185164A1 (fr) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Molécules de liaison à l'antigène her3
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
GB201913079D0 (en) 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules

Also Published As

Publication number Publication date
US20200299413A1 (en) 2020-09-24
RU2019134211A3 (fr) 2021-06-11
JP2020515253A (ja) 2020-05-28
MX2019011585A (es) 2020-02-17
KR20190141154A (ko) 2019-12-23
BR112019019998A2 (pt) 2020-04-28
RU2019134211A (ru) 2021-04-28
JP2023175760A (ja) 2023-12-12
IL269559B2 (en) 2024-06-01
CN111094355A (zh) 2020-05-01
CA3057567C (fr) 2024-06-25
EP3601366A1 (fr) 2020-02-05
IL269559A (en) 2019-11-28
JP7432365B2 (ja) 2024-02-16
IL269559B1 (en) 2024-02-01
CA3057567A1 (fr) 2018-10-04
WO2018178101A1 (fr) 2018-10-04
US11560437B2 (en) 2023-01-24
AU2018241881A1 (en) 2019-11-07
ZA201906981B (en) 2020-09-30

Similar Documents

Publication Publication Date Title
SG11201908825TA (en) Stable multispecific antibodies
SG11201909949XA (en) Targeted immunotolerance
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201909011PA (en) Niraparib compositions
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer